ARS Pharmaceuticals
SPRY
97 hedge funds and large institutions have $252M invested in ARS Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 38 increasing their positions, 22 reducing their positions, and 18 closing their positions.
73% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 22
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
28% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 18
13% more call options, than puts
Call options by funds: $4.33M | Put options by funds: $3.83M
11.51% more ownership
Funds ownership: 58.11% → 69.62% (+12%)
5% more funds holding
Funds holding: 92 → 97 (+5)
32% less capital invested
Capital invested by funds: $369M → $252M (-$117M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$42.3M |
| 2 |
CST
Charles Schwab Trust
Henderson,
Nevada
|
+$27.9M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$25.4M |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$8.4M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$6.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$22M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$14.2M |
| 3 |
Two Sigma Investments
New York
|
-$3.54M |
| 4 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$1.84M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$1.63M |
SPRY Hedge Fund Activity: Q3 2023 in Review
97 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q3 2023, worth a combined $252M — down 32% from $369M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new SPRY positions and 18 closed out — a net gain of 5 holders — while 38 added to existing stakes and 22 trimmed.
The largest buyer was RA Capital Management, adding an estimated $42.3M. The largest seller was Fidelity Investments, cutting an estimated $22M.
- 97 institutional investors held ARS Pharmaceuticals (SPRY) as of Q3 2023, up from 92 in Q2 2023.
- Funds reported $252M of ARS Pharmaceuticals stock for Q3 2023, down 32% quarter-over-quarter.
- 23 funds opened new ARS Pharmaceuticals positions in Q3 2023 and 18 closed out, a net change of +5 holders.
- The largest ARS Pharmaceuticals buyer in Q3 2023 was RA Capital Management, an estimated $42.3M added.
- The largest ARS Pharmaceuticals seller in Q3 2023 was Fidelity Investments, an estimated $22M sold.
Based on aggregated 13F filings for Q3 2023.